On November 4, 2026, alongside its third-quarter results, CVS Health said it intends to separate into two independent, publicly traded companies. Item 7.01 of the company’s Form 8-K says the transaction is intended to be tax-free to the company and its shareholders for U.S. federal income tax purposes. We could not open the press release exhibit, so the structure details below come from AJMC’s report of the announcement; check them against the release.
What was announced
As reported, one company would hold Aetna, CVS Caremark, CVS Specialty, Oak Street Health and Signify Health, with David Joyner, now chairman and CEO of CVS Health, as chairman and CEO. The other, CVS Pharmacy, would hold about 9,000 retail pharmacies, mail pharmacies, MinuteClinic and a technology services business called Health100, with Prem Shah, now group president, as CEO. CVS Health shareholders would own shares in both. The separation is expected by the first half of 2028 and depends on customary conditions, including final board approval and the effectiveness of a Form 10 registration statement. It would reverse the roughly $78 billion Aetna acquisition completed in 2018. CNBC reported that CVS shares fell about 10% on the day; we did not verify the closing price.
The quarter it was announced with
| Three months ended Sept 30 | 2026 | 2025 |
|---|---|---|
| Total revenues | $108,399M | $102,871M |
| Net income attributable to CVS Health | $2,172M | $(3,975)M |
| Diluted EPS | $1.68 | $(3.13) |
| Health Care Benefits revenue | $36,855M | $35,993M |
| Health Services revenue | $53,964M | $49,266M |
| Pharmacy & Consumer Wellness revenue | $35,498M | $36,214M |
Source: CVS Health Form 10-Q for the quarter ended September 30, 2026. Segment revenues are before intersegment eliminations of $(18,123)M in 2026 and $(18,735)M in 2025.
Revenue grew 5.4% to $108,399M (our arithmetic), led by Health Services, up 9.5%, while Pharmacy & Consumer Wellness fell 2.0%. Net income attributable to CVS Health was $2,172M against a loss of $3,975M a year earlier; we have not looked into what drove the prior-year loss, so do not read the swing as an operating trend. CVS’s reporting segments do not map one-for-one to the two planned companies, and we did not find pro forma financials for either.
What is not yet known
In the sources we read, there is no final name for the pharmacy company, no board or remaining leadership, no allocation of debt between the two companies, no capital return plans for either, and no Form 10 yet. Those are the items that would let an investor value the two companies separately, and until they arrive any sum-of-the-parts figure would be our assumption, not the company’s. We do not cover CVS with a rating, and nothing here is a recommendation.
Also this week: the September trade deficit
The Bureau of Economic Analysis and the Census Bureau reported on November 4 that the U.S. goods and services trade deficit was $105.0 billion in September, down $0.7 billion from $105.7 billion in August (revised). Exports rose $5.8 billion (1.9%) to $321.5 billion and imports rose $5.2 billion (1.2%) to $426.6 billion. The goods deficit was $135.9 billion and the services surplus $30.9 billion. The next release is December 8. Source: BEA, U.S. International Trade in Goods and Services, September 2026.
Disclosures. Insights are commentary drawn from NovaRock’s published notes and the filings behind them. They are not research notes, they do not change any rating or fair value, and they are not personalized investment advice or an offer to buy or sell any security. Drafting uses AI-assisted research tools. Full disclosures are on our legal pages. Not marketed or offered to residents of India.